Targeted assessment of enlargement of the perivascular space in Alzheimer’s disease and vascular dementia subtypes implicates astroglial involvement specific to Alzheimer’s disease

Manuscript Number: 

18-0367R3

Author(s): 
Erin L. Boespflug, Marjorie Grafe, Jeffrey J. Iliff, Jeffrey A. Kaye, Emmalyn Leonard, Lisa Silbert, Matthew J. Simon, Randall L. Woltjer

Disclosures

Erin L. Boespflug

  • Nothing to Disclose

Marjorie Grafe

  • Nothing to Disclose

Jeffrey J. Iliff

  • Consulting Fees:
    Served as consultant to GlaxoSmithKline.
    Lecture Fees:
    Received lecture fee for talk given for Neurim Pharmaceuticals.
    Grants
    • Agency: 
      GlaxoSmithKline
      Dates: 
      2016-2018

Jeffrey A. Kaye

  • Consulting Fees:
    Data Safety Monitoring Boards for Suven Pharmaceuticals and Eli Lilly. Paid for this activity each < $5000 in last 12 months.
    Patents/Royalties
    Named in Oregon Health & Science University intellectual property case #2030 (METHOD FOR CONDUCTING CLINICAL TRIALS BASED ON SUBSTANTIALLY CONTINUOUS MONITORING OF OBJECTIVE QUALITY OF LIFE FUNCTIONS). Licence paid to OHSU for this (I recieved $266).
    Grants
    • Agency: 
      Dr. Kaye receives research support from the NIH (U2C AG054397, P30 AG008017, R01 AG024059, P30 AG024978, P01 AG043362, U01 AG010483) and Merck; directs a center that receives research support from the NIH, CDC, Alzheimer’s Association, AbbVie, Kyowa, Glov
      Dates: 
      2016-2018

Emmalyn Leonard

  • Nothing to Disclose

Lisa Silbert

  • Nothing to Disclose

Matthew J. Simon

  • Nothing to Disclose

Randall L. Woltjer

  • Nothing to Disclose